welcome
Reuters

Reuters

Health

Health

GSK resolves patent lawsuit against Pfizer over RSV vaccines

Reuters
Summary
Nutrition label

76% Informative

GlaxoSmithKline and Pfizer have agreed to end a lawsuit that alleged Pfizer 's respiratory syncytial virus ( RSV ) vaccine Abrysvo violated GSK 's patent rights in its competing RSV shot Arexvy.

The respiratory disease typically causes cold-like symptoms, but it is also a leading cause of pneumonia in toddlers and older adults.

GSK , Pfizer and Moderna have developed RSV shots approved by the U.S. Food and Drug Administration .

VR Score

87

Informative language

94

Neutral language

21

Article tone

formal

Language

English

Language complexity

58

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links